REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...

Exicure’s significant layoffs and recent shelving of research activities haven’t yet attracted a transaction to save the remainder of the business. The biotech’s recently appointed joint CEO and chief ...

Shares of low-float micro-cap stock Exicure Inc (NASDAQ:XCUR) are rocketing higher in Wednesday’s after-hours session after the company announced that it received an extension from the Nasdaq Hearings ...

A startup dream has been realized, while an old pharma company tries to turn a new leaf. For that investment, Purdue gets an option and licensing agreement for an investigational psoriasis drug and ...

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that in connection with the change of control transaction approved by the stockholders at the Special ...

Exicure, Inc. (NADAQ:XCUR) stock is trading higher on Monday after the company entered into debt-for-equity exchange agreements. What Happened: On Friday, Exicure filed a Form 8-K with the Securities ...

We recently compiled a list of the 10 Micro-, Small-Cap Companies Lead Monday's Charge. In this article, we are going to take a look at where Exicure Inc. (NASDAQ:XCUR) stands against the other stocks ...

The company states: “Exicure (XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In ...

Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and ...

Exicure, Inc. (NASDAQ:XCUR) announced Thursday that it has achieved the first milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc. The milestone was reached through the ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient ...